tradmap

TCRX TScan Therapeutics, Inc.

$0.93 +2.38%

Healthcare · Biological Products, (No Diagnostic Substances)

TScan Therapeutics, Inc. (TCRX) is a healthcare company in the Biological Products, (No Diagnostic Substances) industry, with a market capitalization of $120 million. Shares last traded at $0.93, 63.9% below their 52-week high. Over the past year the stock is down 40.3%. Net profit margin is -1256.8%, below the peer median of 6.3%. Revenue grew 266.7% year over year.

Market Cap
$120M
Shares Out
129.9M
EPS (TTM)
$-1.85
P/E Ratio
P/S Ratio
11.65
P/B Ratio
1.24
Dividend / Share
Dividend Yield
52-Week High
$2.56
52-Week Low
$0.86
Volume
5,563
Avg Vol (3m)
32,482.143

Performance

1W
+0.58%
1M
-4.61%
3M
-11.43%
6M
-2.88%
YTD
-9.70%
1Y
-40.29%

Daily candles · volume · SMA(20)/SMA(50) · Databento EQUS.MINI.

Technicals

RSI (14)
41.89
SMA (50)
$1.09
SMA (200)
$1.27
Price vs SMA50
-15.32%
Price vs SMA200
-27.05%
ATR (14)
$0.06

Financials

Revenue
$10M
Net Income
$-130M
Gross Margin
Operating Margin
-1315.4%
Net Margin
-1256.8%
Return on Equity
-133.9%
Return on Assets
-64.2%
Current Ratio
6.65
Debt / Equity
0.34
Revenue Growth (YoY)
+266.7%

Latest reported annual period ending 2025-12-31 · SEC EDGAR/XBRL.

Recent earnings

PeriodEPS (diluted)Reported
Q1 2026 $-0.22 2026-05-06
FY 2025 $-1.00 2026-03-04
Q3 2025 $-0.82 2025-11-12
Q2 2025 $-0.55 2025-08-12
Q1 2026 $-0.26 2026-05-06
FY 2025 $-1.14 2026-03-04

Full earnings history →

Biological Products, (No Diagnostic Substances) peers

TCRX vs 14 industry peers (Biological Products, (No Diagnostic Substances)), by market cap.

P/S vs peers
11.65 / 5.21 med
+123% premium
Net margin vs peers
-1256.8% / 6.3% med
below median
1–14 of 14
AMGNAmgen$182.1B23.624.9621.0%-1.27%
GILDGilead Sciences$153.5B18.045.2128.9%-1.46%
RVMDRevolution Medicines, Inc.$34.6B-30.62+3.14%
BIIBBiogen$29.0B22.442.9313.1%-1.15%
MRNAModerna$25.4B-8.99+3.22%
NBIXNeurocrine Biosciences Inc$15.9B33.245.5616.7%-0.48%
EXELExelixis, Inc.$13.1B16.685.6233.7%-1.04%
KRYSKrystal Biotech, Inc.$10.2B50.0226.3352.6%+1.68%
TECHBio-Techne$9.1B123.617.446.0%+5.36%
HALOHalozyme Therapeutics, Inc.$8.1B25.675.8222.7%-0.03%
IBRXImmunitybio, Inc.$7.7B-21.87+5.01%
RGENRepligen Corp$7.4B152.2710.086.6%-1.20%
KYMRKymera Therapeutics, Inc.$7.4B23.88+0.44%
PCVXVaxcyte, Inc.$7.4B-9688.00+1.57%

Source: SEC EDGAR (fundamentals/EPS/dividends) · Databento EQUS.MINI (prices) · market cap & yield computed by tradmap. Informational only — not financial advice.